A Randomised Controlled Phase II Trial of the Combination of XELOX with Thalidomide for the First-line Treatment of Metastatic Colorectal Cancer

OBJECTIVE: To evaluate the efficacy and safety of the combination of XELOX regimen (oxaliplatin plus capecitabine) with thalidomide for the first-line treatment of metastatic colorectal cancer (MCRC). METHODS: All of the 89 patients with MCRC who fulfilled eligibility criteria were randomly assigned...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Jing, Liu, Ning, Liu, Ke-wei, Ding, Ai-ping, Wang, Hao, Qiu, Wen-sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643658/
https://www.ncbi.nlm.nih.gov/pubmed/23691464
http://dx.doi.org/10.3969/j.issn.2095-3941.2012.02.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643658/
https://www.ncbi.nlm.nih.gov/pubmed/23691464
http://dx.doi.org/10.3969/j.issn.2095-3941.2012.02.005

Ejemplares similares